Visby Medical announced two new relationships that will expand national access to the Visby Women's Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexual transmitted infections (STIs) available to consumers, enabling immediate access to Visby's integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomoniasis from the comfort and privacy of the home. The need for accessible testing is urgent.
Almost 100,000 women in the U.S. lose their fertility every year due to complications from untreated STIs. These infections are often "silent," presenting with no symptoms while causing irreversible damage to the reproductive system. Current barriers to testing contribute to delayed treatment and increased transmission.
To address this, in November 2025, questhealth.com, the consumer-initiated testing offering of Quest Diagnostics ("Quest"), added the Visby Medical's at-home Women's Sexual Health Test to its array of offerings supporting women's health. The expansion of availability of Visby's Women Sexual Health Test comes on the heels of Visby Medical's nationwide launch of its STI test in November, removing long-standing gaps in care.
